Overview: Somatostatin TestIntroduction: The Somatostatin Test measures somatostatin to diagnose neuroendocrine tumors, causing abdominal pain. Aligned with 2023 NANETS guidelines, it uses biochemical methods for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in biochemistry for patients with suspected neuroendocrine tumors.
Other Names: Somatostatin Assay, Neuroendocrine Hormone Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: Somatostatin testing began in the 1970s with neuroendocrine research. Biochemical methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures somatostatin to diagnose neuroendocrine tumors, guides treatment, and evaluates patients with abdominal pain.
Test Parameters: 1. Somatostatin Level
Pretest Condition: Fasting for 10-12 hours required. Collect serum or plasma. Report history of abdominal pain or neuroendocrine symptoms.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document abdominal pain, diarrhea, or history of neuroendocrine tumors. Include current medications, especially octreotide.
Consent: Written consent required, detailing the tests purpose, neuroendocrine tumor implications, and risks of sample collection.
Procedural Considerations: Uses radioimmunoassay or ELISA to measure somatostatin levels. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for neuroendocrine tumor diagnosis.
Factors Affecting Result Accuracy: Improper fasting or sample hemolysis can affect results. Medications like octreotide may alter levels.
Clinical Significance: Elevated somatostatin confirms neuroendocrine tumors, guiding octreotide therapy or surgery. Normal levels may require chromogranin A testing.
Specialist Consultation: Consult an oncologist or endocrinologist for result interpretation and treatment planning.
Additional Supporting Tests: Chromogranin A, 5-HIAA, or imaging to confirm neuroendocrine tumor diagnosis.
Test Limitations: Non-specific for certain neuroendocrine tumors; clinical correlation is needed. Sample quality affects sensitivity.
References: NANETS Neuroendocrine Guidelines, 2023; Journal of Clinical Oncology, Oberg K, 2022.
